Department of Family Medicine

Original Article: Community Advisors’ Effect on a Randomized Pragmatic Clinical Trial for Asthma Treatment—Retrospective Analysis

Written by Brittany Manansala | December 22, 2025

“Community Advisors’ Effect on a Randomized Pragmatic Clinical Trial for Asthma Treatment: Retrospective Analysis.”

JMIR

December 2025

Elizabeth Staton, MS, Senior Instructor for the University of Colorado Anschutz Department of Family Medicine (DFM), is a coauthor of the recent Journal of Medical Internet Research (JMIR) article, “Community Advisors’ Effect on a Randomized Pragmatic Clinical Trial for Asthma Treatment: Retrospective Analysis."

This study highlights the impact that community advisors, such as patients, families, clinicians, and payers, can have in guiding clinical research. Through the Person Empowered Asthma Relief (PREPARE) randomized clinical trial, researchers examined the role of community advisors in addressing implementation concerns related to using inhaled corticosteroids (ICS) as part of rescue therapy for asthma.

From the article:

“Community advisors addressed 2 issues that threatened the success of the research: low response rates to monthly outcome surveys and low reported use of ICS with nebulizer rescue treatments. Initial low survey response rates were addressed by changing reminder frequency, shortening the survey, reducing the burden of logging in, and adding a raffle prize for timely responses. In the pilot phase of the study, the overall 3-month survey response rate was 67% (64 completed of 96 possible surveys). After protocol changes, the survey response rate over the first 3 months was 96.08% (3404 completed of 3543 possible surveys) and was 87.38% (1032 of 1181 participants) for each individual’s final 3 months; the overall response rate for the full study was 92.3%. For the full study, 72.1% (n=850) of 1181 participants completed all of their first three surveys compared with only 25% (n=8) of 32 pilot enrollees. Early low use of ICS with nebulizers was addressed by additional communication, reminder stickers, and designing a method to attach a provided ICS inhaler to the nebulizers. The percentage of people reporting use of 3 to 5 puffs of ICS with each nebulizer treatment rose from 42.1% (200/475) in the early full study to 75.4% (525/696) following the protocol changes.”

Other members of the DFM associated with this publication: Wilson Pace, MD (emeritus professor). 

Read more of this article through JMIR Publications.

(Cover photo credit from the JMIR Publications.)